Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical guide to the legal status of compounded estradiol patches, FDA-approved alternatives, 503A and 503B compounding rules, and safety considerations for transdermal estradiol therapy.
Read clinical reviewAnalysis of FDA FAERS safety signals for estradiol transdermal patches (Climara, Vivelle-Dot, Minivelle), including VTE risk, cardiovascular events, and how patch data compares to oral estrogen surveillance.
Read clinical reviewA complete timeline of estradiol transdermal patch FDA approvals, label changes, boxed warnings, and post-market safety data from Estraderm through Minivelle.
Read clinical reviewA clinical review of estradiol transdermal patch regulatory history, patent disputes, generic entry timelines, FDA labeling changes, and ongoing legal considerations for Climara, Vivelle-Dot, and Minivelle.
Read clinical reviewA clinical review of the estradiol transdermal patch pipeline, including FDA-approved products, emerging next-generation delivery systems, updated safety data, and prescribing label details for hormone replacement therapy.
Read clinical reviewA clinical comparison of how the FDA and EMA regulate estradiol transdermal patches, including approval history, labeling differences, post-market surveillance, and what these divergences mean for prescribers and patients.
Read clinical review